259 related articles for article (PubMed ID: 21878861)
1. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis.
Szypowska A; Golicki D; Groele L; Pańkowska E
Pol Arch Med Wewn; 2011; 121(7-8):237-46. PubMed ID: 21878861
[TBL] [Abstract][Full Text] [Related]
2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
3. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
4. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
5. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
6. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
Standl E; Lang H; Roberts A
Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
Bartley PC; Bogoev M; Larsen J; Philotheou A
Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
[TBL] [Abstract][Full Text] [Related]
8. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.
Tricco AC; Ashoor HM; Antony J; Beyene J; Veroniki AA; Isaranuwatchai W; Harrington A; Wilson C; Tsouros S; Soobiah C; Yu CH; Hutton B; Hoch JS; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
BMJ; 2014 Oct; 349():g5459. PubMed ID: 25274009
[TBL] [Abstract][Full Text] [Related]
9. Insulin detemir: a review of its use in the management of diabetes mellitus.
Keating GM
Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609
[TBL] [Abstract][Full Text] [Related]
10. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
Monami M; Marchionni N; Mannucci E
Diabetes Obes Metab; 2009 Apr; 11(4):372-8. PubMed ID: 19267715
[TBL] [Abstract][Full Text] [Related]
11. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.
Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
Pediatr Diabetes; 2011 Nov; 12(7):632-41. PubMed ID: 21418455
[TBL] [Abstract][Full Text] [Related]
12. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
[TBL] [Abstract][Full Text] [Related]
13. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.
Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
Diabet Med; 2013 Feb; 30(2):216-25. PubMed ID: 23094597
[TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
15. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
16. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.
Home P; Bartley P; Russell-Jones D; Hanaire-Broutin H; Heeg JE; Abrams P; Landin-Olsson M; Hylleberg B; Lang H; Draeger E;
Diabetes Care; 2004 May; 27(5):1081-7. PubMed ID: 15111525
[TBL] [Abstract][Full Text] [Related]
17. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
[TBL] [Abstract][Full Text] [Related]
18. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
Garber AJ; Clauson P; Pedersen CB; Kølendorf K
J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons.
Sanches AC; Correr CJ; Venson R; Pontarolo R
Diabetes Res Clin Pract; 2011 Dec; 94(3):333-9. PubMed ID: 21992870
[TBL] [Abstract][Full Text] [Related]
20. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.
De Leeuw I; Vague P; Selam JL; Skeie S; Lang H; Draeger E; Elte JW
Diabetes Obes Metab; 2005 Jan; 7(1):73-82. PubMed ID: 15642078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
